

Name of the Listed Entity : ASTRAZENECA PHARMA INDIA LIMITED  
Quarter ending : September 30, 2017

ANNEXURE 1

I. Composition of Board Directors									
Title (Mr./Ms.)	Name of the Director	PAN	DIN	Category (Chairperson/Executive/Non- Executive/ Independent/Nominee)	Date of Appointment in the current term/cessation	Tenure*	No. of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	No. of Memberships in Audit/Stakeholder Committee(s) including this listed entity(Refer Regulation 26(1) of Listing Regulations)	No. of Post of Chairperson in Audit/Stakeholder Committee held in listed entities including this listed entity(Refer Regulation 26(1) of Listing Regulations)
Mr.	NARAYAN KEELVEEDHI SESHADRI	AAVPS2486D	00053563	Non-Executive/Independent	30/09/2014	5 years	6	7	3
Ms.	REVATHY ASHOK	ACLPR3951Q	00057539	Non-Executive/Independent	02/12/2016	5 years	4	7	3
Ms.	KIMSUKA NARASIMHAN	AAKPK7372B	02102783	Non-Executive/Independent	02/02/2017	5 years	2	1	0
Mr.	GAGAN SINGH BEDI	AAKPB3168Q	07844333	Executive	01/07/2017		1	1	0
Mr.	GREGORY DAVID EMIL MUELLER	PAN not available	07667074	Non-Executive	02/12/2016		1	1	0
Mr.	IAN JOHN PARISH	PAN not available	00391534	Non-Executive	08/08/2017		1	0	0
Mr.	RAJESH MARWAHA	AAAPM1413D	01458768	Executive	02/12/2016		1	1	0



II. Composition of Committees		
Name of Committee	Name of Committee members	Category(Chairperson/Executive/Non-Executive/Independent/Nominee)
Audit Committee	1. Ms. REVATHY ASHOK	Chairperson/Non-Executive/Independent
	2. Mr. NARAYAN K SESHADRI	Non-Executive/Independent
	3. Mr. GREGORY DAVID EMIL MUELLER	Non-Executive
Nomination and Remuneration Committee	1. Ms. KIMSUKA NARASIMHAN	Chairperson/Non-Executive/Independent
	2. Mr. NARAYAN K SESHADRI	Non-Executive/Independent
	3. Mr. GREGORY DAVID EMIL MUELLER	Non-Executive
	4. Mr. IAN JOHN PARISH	Non-Executive
Stakeholders' Relationship Committee	1. Ms. REVATHY ASHOK	Chairperson/Non-Executive/Independent
	2. Mr. GAGAN SINGH BEDI	Executive
	3. Mr. RAJESH MARWAHA	Executive

III. Meeting of Board of Directors		
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive meetings (in number of days)
9 May 2017	8 August 2017	39 days
29 June 2017	13 September 2017	

IV. Meeting of Committees			
Date(s) of meeting of the Committee in the relevant quarter	Whether requirement of Quorum met (details)	Date (s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days*
<b>Audit Committee</b>			
8 August 2017	Yes	8 May 2017	91 days
<b>Nomination &amp; Remuneration Committee</b>			
8 August 2017	Yes	9 May 2017	92 days



<b>V. Related Party Transactions</b>	
<i>Subject</i>	<i>Compliance status (Yes / No / NA) refer note below</i>
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit committee	Yes

Details of material transactions with Related Party for the quarter ended September 30, 2017

Name of the Related Party: **AstraZeneca UK Limited**

<b>Type of Transaction</b>	<b>Amount (INR)</b>
Imports	529,685,347
Payable of Expenses	2,997,319
Reimbursement of Expenses	2,388,645
<b>Total</b>	<b>535,071,311</b>



## Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
2. The Composition of the following committees is in terms of SEBI (listing Obligations and Disclosure requirements) Regulations, 2015
  - a) Audit Committee
  - b) Nomination & Remuneration Committee
  - c) Stakeholders Relationship Committee
3. The Committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements Regulations, 2015
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
5. This report and /or the report submitted in the previous quarter has been placed before Board of Directors.

Any comments/observations/advice of Board of Directors may be mentioned here:  
NIL

For AstraZeneca Pharma India Limited



Pratap Rudra  
Company Secretary & Legal Counsel





### ANNEXURE III

**Format to be submitted by listed entity at the end of 6 months after end of financial year along-with second quarter report of next financial year**

Affirmations		
Broad heading	Regulation Number	Compliance status (Yes/No/NA)
Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on website	46(2)	Yes
Presence of Chairperson of Audit Committee at the Annual General Meeting	18(1)(d)	Yes
Presence of Chairperson of the nomination and remuneration committee at the annual general meeting	19(3)	No(*)
Whether "Corporate Governance Report" disclosed in Annual Report	34(3) read with para C of Schedule V	Yes

(\*) Pursuant to clause 19(3), presence of Chairman of the Nomination and Remuneration Committee in the Annual General Meeting is not a mandatory requirement.

#### Note

- 1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A.. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.
- 2 If status is "No" details of non-compliance may be given here.
- 3 If the Listed Entity would like to provide any other information the same may be indicated here.



**Pratap Rudra**  
Company Secretary & Legal Counsel

